Myelin oligodendrocyte glycoprotein-specific peptide for the treatment or prevention of multiple sclerosis

Abstract

Compositions for the treatment or prevention of multiple sclerosis are provided. In some embodiments, the composition comprises an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) protein, wherein the peptide activates regulatory T cells. In some embodiments, the composition comprises dendritic cells pulsed with a MOG peptide that activates regulatory T cells. In some embodiments, the peptide activates HLA-E-restricted regulatory CD8+ T cells.

What is claimed is: 
     
         1 . A composition for the treatment or prevention of multiple sclerosis, the composition comprising an isolated peptide comprising a partial amino acid sequence of a myelin oligodendrocyte glycoprotein (MOG) protein, wherein the peptide activates regulatory T cells. 
     
     
         2 . The composition of  claim 1 , wherein the peptide comprises a MOG-specific MHC1b epitope. 
     
     
         3 . The composition of  claim 2 , wherein the peptide comprises a HLA-E epitope. 
     
     
         4 . The composition of any of  claims 1  to  3 , wherein the peptide comprises the amino acid sequence IICYNWLHR. 
     
     
         5 . The composition of any of  claims 1  to  3 , wherein the peptide consists of the amino acid sequence IICYNWLHR. 
     
     
         6 . The composition of any of  claims 1  to  5 , wherein the peptide activates HLA-E-restricted regulatory CD8 +  T cells. 
     
     
         7 . A composition for the treatment or prevention of multiple sclerosis, the composition comprising dendritic cells pulsed with a myelin oligodendrocyte glycoprotein (MOG) peptide that activates regulatory T cells. 
     
     
         8 . The composition of  claim 7 , wherein the peptide activates HLA-E-restricted regulatory CD8 +  T cells. 
     
     
         9 . The composition of  claim 7  or  8 , wherein the peptide comprises a MOG-specific MHC1b epitope. 
     
     
         10 . The composition of  claim 8 , wherein the peptide comprises a HLA-E epitope. 
     
     
         11 . The composition of any of  claims 7  to  10 , wherein the peptide comprises the amino acid sequence IICYNWLHR. 
     
     
         12 . The composition of any of  claims 7  to  10 , wherein the peptide consists of the amino acid sequence IICYNWLHR. 
     
     
         13 . The composition of any of  claims 7  to  12 , wherein the dendritic cells are derived from myelin-specific pathogenic autoimmune cells. 
     
     
         14 . The composition of any of  claims 7  to  12 , wherein the dendritic cells are derived from monocytes. 
     
     
         15 . A method of treating or preventing a demyelinating disease, the method comprising administering to a subject the composition of any of  claims 1  to  14 . 
     
     
         16 . The method of  claim 15 , wherein the demyelinating disease is selected from the group consisting of multiple sclerosis, idiopathic inflammatory demyelinating disease, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, leukoystrophy, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, autoimmune peripheral neuropathy, Charcot-Marie-Tooth disease, acute disseminated encephalomyelitis, adrenoleukodystrophy, adrenomyeloneuropathy, Leber's hereditary optic neuropathy, or HTLV-associated myelopathy. 
     
     
         17 . The method of  claim 16 , wherein the demyelinating disease is multiple sclerosis. 
     
     
         18 . The method of  claim 15 , wherein the subject has multiple sclerosis. 
     
     
         19 . The method of any of  claims 15  to  18 , wherein the composition is administered subcutaneously or intravenously. 
     
     
         20 . A method of treating multiple sclerosis, the method comprising administering to a subject having multiple sclerosis a composition comprising dendritic cells pulsed with a myelin oligodendrocyte glycoprotein (MOG) peptide that activates HLA-E-restricted regulatory CD8 +  T cells. 
     
     
         21 . The method of  claim 20 , wherein the peptide comprises or consists of the amino acid sequence IICYNWLHR. 
     
     
         22 . The method of  claim 20  or  21 , wherein the dendritic cells are derived from monocytes that are autologous to the subject.